Broadcast Date: September 30, 2022
Weather: 8:00 a.m. Pacific Time, 11:00 a.m. Eastern Time, 5:00 p.m. CET
The potential of gene editing as a therapy has been realized in recent years, as clinical data from several studies have shown very positive results. Fusing that potential with new mRNA technologies, which have also proven their value and versatility during the COVID-19 pandemic, could provide scientists and clinicians with an unparalleled weapon in the arsenal to combat various diseases. In particular, Cas13 has been used to target RNA viruses in cell culture, but its efficacy has only recently been demonstrated in animal models.
This is the third webinar in a series of four, co-hosted by GEN and The CRISPR Journal, delving into the burgeoning world of mRNA research and therapeutics. Our distinguished guest for this event, Dr Felipe Santangelo, will present important aspects on how to use mRNA to express Cas13 and use it as an antiviral agent. Additionally, Dr. Santangelo will discuss guideline design, detection, the importance of controls, and how to apply this approach in vivo against multiple pathogens.
A live Q&A session followed the presentation, offering the opportunity to pose questions to our expert panelist.